-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 DetzoZyyyZInOZVRqds6Y3/WmFZJtwwfzGzc/tBVo+iUDz1tSHrEYywKXerLqLKG
 0zN6DC0ufP0AyA4bA+KuLw==

<SEC-DOCUMENT>0000950123-10-069679.txt : 20100729
<SEC-HEADER>0000950123-10-069679.hdr.sgml : 20100729
<ACCEPTANCE-DATETIME>20100729142416
ACCESSION NUMBER:		0000950123-10-069679
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20100728
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20100729
DATE AS OF CHANGE:		20100729

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GeoVax Labs, Inc.
		CENTRAL INDEX KEY:			0000832489
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				870455038
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52091
		FILM NUMBER:		10977387

	BUSINESS ADDRESS:	
		STREET 1:		1900 LAKE PARK DRIVE
		STREET 2:		SUITE 380
		CITY:			SMYRNA
		STATE:			2Q
		ZIP:			30080
		BUSINESS PHONE:		678-384-7220

	MAIL ADDRESS:	
		STREET 1:		1900 LAKE PARK DRIVE
		STREET 2:		SUITE 380
		CITY:			SMYRNA
		STATE:			2Q
		ZIP:			30080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Geovax Labs, Inc.
		DATE OF NAME CHANGE:	20061002

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DAUPHIN TECHNOLOGY INC
		DATE OF NAME CHANGE:	19940826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SUCCESSO INC
		DATE OF NAME CHANGE:	19910410
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>c04009e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">
<DIV style="font-size: 10pt">
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 2pt solid">&nbsp;</DIV>
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 1pt solid">&nbsp;</DIV>

<P style="font-size: 14pt" align="center"><B>UNITED STATES<BR>
SECURITIES AND
EXCHANGE COMMISSION<BR>
<FONT style="font-size: 12pt">Washington, D.C. 20549
</FONT></B>

<P style="font-size: 18pt" align="center"><B>FORM 8-K</B>

<P style="font-size: 12pt" align="center"><B>CURRENT REPORT<BR>
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934</B>

<P style="font-size: 10pt" align="center"><B>Date of Report (Date of earliest
event reported): July 28, 2010</B>



<P style="font-size: 24pt" align="center"><B>GEOVAX LABS, INC.<BR>
</B><FONT
style="font-size: 10pt">(Exact name of registrant as specified in its charter)
</FONT>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="100%" border="0">

 <TR>
  <TD width="32%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="33%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="32%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>Delaware</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>000-52091</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>87-0455038</B></TD>
 </TR>
 <TR valign="top">
  <TD>(State or other Jurisdiction of Incorporation)</TD>
  <TD>&nbsp;</TD>
  <TD>(Commission File Number)</TD>
  <TD>&nbsp;</TD>
  <TD>(IRS Employer Identification No.)</TD>
 </TR>

</TABLE>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="100%" border="0">

 <TR>
  <TD width="49%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="49%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>1900 Lake Park Drive, Suite
380<BR>
Smyrna, Georgia<BR>
</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>30080</B></TD>
 </TR>
 <TR valign="top">
  <TD>(Address of Principal Executive Offices)</TD>
  <TD>&nbsp;</TD>
  <TD>(Zip Code)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="center">Registrant&#8217;s telephone number,
including area code: <B>(678) 384-7220</B>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="30%" border="0">

 <TR>
  <TD width="100%">&nbsp;</TD>
 </TR>
 <TR>
  <TD style="border-bottom: #000000 1px solid" nowrap><B>&nbsp;</B></TD>
 </TR>
 <TR>
  <TD nowrap>(Former name or former address if changed since last report.)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="left">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:

<P style="font-size: 10pt" align="left"><FONT face="Wingdings">o</FONT> Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)<BR>
<BR>
<FONT face="Wingdings">o</FONT> Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<BR>



<DIV
style="margin-top: 10pt; font-size: 1pt; width: 100%; border-bottom: black 1pt solid">&nbsp;</DIV>
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 2pt solid">&nbsp;</DIV>
</DIV>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">This Form 8-K and other reports filed by GeoVax Labs, Inc. (the &#147;Registrant&#148;) from time to
time with the Securities and Exchange Commission (collectively the &#147;Filings&#148;) contain forward
looking statements and information that are based upon beliefs of, and information currently
available to, the Registrant&#146;s management as well as estimates and assumptions made by the
Registrant&#146;s management. When used in the Filings the words &#147;anticipate&#148;, &#147;believe&#148;, &#147;estimate&#148;,
&#147;expect&#148;, &#147;future&#148;, &#147;intend&#148;, &#147;plan&#148; or the negative of these terms and similar expressions as they
relate to the Registrant or the Registrant&#146;s management identify forward looking statements. Such
statements reflect the current view of the Registrant with respect to future events and are subject
to risks, uncertainties, assumptions and other factors relating to the Registrant&#146;s industry,
operations and results of operations and any businesses that may be acquired by the Registrant.
Should one or more of these risks or uncertainties materialize, or should the underlying
assumptions prove incorrect, actual results may differ significantly from those anticipated,
believed, estimated, expected, intended or planned.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Item&nbsp;8.01 Other Events.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On July&nbsp;28, 2010, GeoVax Labs, Inc. (the &#147;Company&#148;) issued a press release providing an update
on its deferred offering of shares and warrants.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">A copy of the press release issued by the Company is attached hereto as Exhibit&nbsp;99.1.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Item&nbsp;9.01 Financial Statements and Exhibits.</B>
</DIV>


<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">(d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Exhibits</TD>
</TR>

</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="8%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="87%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left"><B><u>Exhibit No.</u></B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left"><B><u>Description of Exhibit</u></B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Exhibit&nbsp;99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press Release</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>SIGNATURE</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Dated: July&nbsp;29, 2010
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">GEOVAX LABS, INC.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Mark W. Reynolds
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Mark W. Reynolds&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Chief Financial Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>

</TABLE>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>EXHIBIT INDEX</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="8%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="87%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left"><B><u>Exhibit No.</u></B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left"><B><u>Description of Exhibit</u></B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Exhibit&nbsp;99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press Release</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>



<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>c04009exv99w1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 99.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="right" style="font-size: 10pt; margin-top: 10pt"><B><u>Exhibit&nbsp;99.1</u></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><IMG src="c04009p0400901.gif" alt="(GEOVAX LOGO)">
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>GEOVAX LABS, INC. FINANCING UPDATE</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>ATLANTA, GA, July&nbsp;28, 2010 </B>&#151; GeoVax Labs, Inc. (OTC BB: GOVX), an Atlanta-based, biopharmaceutical
firm (the &#147;Company&#148;) developing human vaccines and therapeutics for diseases caused by HIV-1 (Human
Immunodeficiency Virus), previously announced that it has deferred the offering it filed with the
Securities and Exchange Commission to sell shares and warrants. The Company cited a decline in its
share price that coincided with turbulent general stock market conditions as a reason for its
decision.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Management is reassessing fundraising options and anticipates commencing a smaller offering of
securities sometime after Labor Day. Details for such an offering have not been finalized, but it
will likely not include selling stockholders. Current thinking is to conduct a $5&nbsp;million to $10
million offering to retail and institutional investors. However, before offering or selling any
securities, the Company will amend its registration statement on file with the Securities and
Exchange Commission to reflect changes in the terms of the proposed offering, and to update other
information.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">GeoVax President and CEO Robert T. McNally, Ph.D. noted, &#147;The offering we deferred was intended to
give us the financial resources to be much more aggressive in our approach to our clinical pathways
but turned out not to be achievable as our stock price declined and general market conditions
deteriorated. The underlying fundamentals at GeoVax and the strength of our science, however, have
not changed. Neither has our enthusiasm for the Company&#146;s prospects or our excitement about
developments with our vaccines. We remain bullish about our science and the potential for our
vaccines and therapeutics.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">&#147;Given the current conditions in the broad market and a stock price we believe undervalues GeoVax,
the decision was made to defer the offering and rethink our strategy,&#148; Dr.&nbsp;McNally continued. &#147;The
reverse stock split we implemented earlier this year brings us closer to meeting requirements for
eventual listing on a major stock exchange, which remains a goal for the Company. A successful
smaller offering later this year will give the Company funds it needs to make solid progress into
2012 while being less dilutive to our shareholders.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Final decisions on conducting a smaller offering will not be made until later.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>A registration statement relating to these securities has been filed with the Securities and
Exchange Commission but has not yet become effective. These securities may not be sold nor may
offers to buy be accepted prior to the time the registration statement becomes effective.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Forward-Looking Statements</I></B><BR>
Certain statements contained in this release, including those relating to postponement of the
offering, as well as statements containing words like &#147;plans,&#148; &#147;expects,&#148; and other similar
expressions in this press release or the Company&#146;s other public communications, are forward-looking
statements that involve a number of risks and uncertainties. All such forward-looking statements
are subject to certain risks and uncertainties that could cause actual results to differ materially
from those in the forward-looking statements. These risks and uncertainties include, but are not
limited to: that we may not obtain the additional funding needed to continue operations after the
end of 2010, the possible adverse impact on the market price of the Company&#146;s shares of common
stock due to the dilutive effect of the securities which may be sold in the offering, and the
possible adverse effect of continuing unfavorable market conditions, as well as other risks and
uncertainties, such as those detailed from time to time in the Company&#146;s Securities and Exchange
Commission filings, including &#147;Risk Factors&#148; in the Company&#146;s most recent Form 10-K. The Company
does not undertake to update its forward-looking statements.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>###</B>
</DIV>



<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>c04009p0400901.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 c04009p0400901.gif
M1TE&.#EAO0!!`/<```!2E`!2G`!:E`!:G`!:I0!CI0!CK0A:G`ACG!!CG!!C
MI1ACG!ACI1AKI2%KI2%SI2ESI2ESK3%SK3%[K3E[K3E[M3F$K3F$M4*$M4J$
MM4J,M5*,M5*,O5*4O5J4O6.4O6.<O6.<QFN<QFNEQG.EQGNEQGNESGNMSH2M
MSH2USHRUSHRUUI2UUI2]UIR]UIR]WIS&UIS&WJ7&UJ7&WJW&WJW.WK7.WK7.
MY[76Y[W6Y\;6Y\;>Y\;>[\[>[\[G[];>[];G[][G[][G]][O]^?O]^_W]^_W
M__?W__?______P``````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````"'Y!```````+`````"]`$$`AP!2E`!2G`!:E`!:
MG`!:I0!CI0!CK0A:G`ACG!!CG!!CI1ACG!ACI1AKI2%KI2%SI2ESI2ESK3%S
MK3%[K3E[K3E[M3F$K3F$M4*$M4J$M4J,M5*,M5*,O5*4O5J4O6.4O6.<O6.<
MQFN<QFNEQG.EQGNEQGNESGNMSH2MSH2USHRUSHRUUI2UUI2]UIR]UIR]WIS&
MUIS&WJ7&UJ7&WJW&WJW.WK7.WK7.Y[76Y[W6Y\;6Y\;>Y\;>[\[>[\[G[];>
M[];G[][G[][G]][O]^?O]^_W]^_W__?W__?______P``````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````````````````C^`),('$BP
MH,&#"!,J7,BPH<.'$"-*G$BQHL6+&#-JW,BQH\>/($.*'$FRI,F3*%->1.(!
M`(`!&8*HG$FS)D(7`UY:L,FSYTP+.0?H\$ET))(B1(@$`:)C1PX;-VS0H"%C
MQHRJ,J;6B)I#1P\@0((4.5+DH0X!+RD472OQJ!`=.62P0$$"!(<,%"`X6)#@
M@`"_+M$*&#"8\`##`@0#2'S@0(($"QQ$L)"!`P@2*%K,L-%#[)$D((+*8$O:
M8!$@<5&,\)!W@=_"`P@<GDV[MNW;N''+GCU80(,-1!(D=C!$;&F?1X#88$%B
MPP37A7<?'KS8,&WIA!?__0LYL@,'>L/^@]^[][%?P"]G8X^-0D50%#0.-)BP
M@00+&T#*'A>)),@-%2!0T$!BLLDF0`!HY01;;(<M=L`"DVUP&0HLN$###3KH
M`,00215AQ%A('!'BB"*.A5128,%EPPPNJ&`""!]H0`%Y04R`X`$_0("`>M,Y
M0`$(*M@0!!+[811$#2AL`(%?##8HV((-/FA!?2ALU@,1^MF$1%(Y5,<!$!0P
MD*!MNQT`P08HU"!3D0TA\8,+($B`@`#2N;18=;,AN``&'Z`@@PY#?,9F!SD!
M8$,2;N7@P@FL+9!8;652$((+/Q#))D%!S/`!!(?M=J=@M`&`@`0>I`F$$9<:
M%,0!+T&@D!'^/="`@@<0))!>;6:"X,*:I2&Q`PH6'!`J6G=V2I@#'ZB0`Q&I
M+E2"82I`1,1_M`IK&P(8H#!443J0(`&=TWV*)X(2Z`J$I<TN=(0#.27`[$1(
M`.&""!-82YL`$I"P@TU"J#`!N(H%EEX`#7C0`A#I1D1#@B!HU(.F#MS:(`4J
M")%2#AXD<!B"+]D)FP,@V)!E0D>VH$)[+*3,@@H5O@N2$2R<@`(*/42$@8+;
M;G1$#B7\6UL"'N104@T8I"<NG@,D\($-J"XT!`H4,-FD;0_P^E$-`!1`0`)6
M+]1#@CN%U"VGT^6$P:$@Y5"TD^)25T$++BMTQ`D+S/82;+V5W<+^2"VX-,`)
M#XF@H`LD'6$#!]86AH'0'`'Q06%''T@8!V@WY`,%#=J=V.8<HT5`M"*M.Y@#
M(R=$A*,#-%"Z2$"4T$#9`WC0=44SO-[YG=4!H$'.#>GP>F%`N]!5#UXUE2%<
M'H`N$@JB-8332R6H1`0*=0?5P`P8D1"`@FT?-D$-$?50]TL'E#"$0PB/%%Q:
M#4V0TP'I2R\"=8>18-$'V04\9@F"/G0$IR]QP+[8$IK!##`A.4C0!GBB`_<E
MB'</`8+@N'>@Q+QD`96#"`F"`H'SD48'0?G`0CR@H!OTY`@@V!X`$A"_AV"N
M6+@+8,TDLBJT(&"&I<D`8=R5$"#8:@#^KB**"A9#`+5`Q`9L4TQB$H##B&SP
M)2CPB(C:TK^!8`V*"6'>2Y0GD!-E:2GO2DX0B`"$N!GD"&,$BQD1HL4!9)`A
M.FQ;L6A`$20`4'4:*<(,/#`!\%!`!&\\2`Y(8('O_(@&@OK?8()X1@@@B(=)
M*((+..``!!S``1IH01!.X!@-8,D%[$H``D1XD!HXH#$'(,'L$+*!PV@`(JQ2
M8K$R4)&OO:1A&9E!!'!#`<89I`<9D-ALOB>0%02%C@:I`8(&0$H;[/(V$6B!
MQ@:0`H&(;S:`*X@/9\-%A@SA?1`1#,<H"#Z*N*`ZR+S(LX)2F_2P()D:DURH
M"!/%(OSPE0;^T8"":N8>Z\RS6"(82`\T]I)T(NJ%`[!?1``#$3')<0`'6.-#
MF/<7"`K$!AW8@`8VH-&.:H`#),A2&P?@`!&<[`._0Q#A!I(#8;T$:.T)`;LD
M%ZT1&.8'VF226G`B.0>0P`4N(`$`%910@LR@.EP;R+-T,A%.,4"#%/Q4`E;W
MD*4B8'8[`%=N"$#*+O5&!4T3"!%(D)X$6"R2['J)!\[:Q1/<[0"=29!"!_+$
M`<B`""X5P`E&=@046/`E<Q5(72=0%B1>D*T0L8`!`LN0((1+,1#UX$1.0!CX
M&80%]X+=8@+P`"+=["\&)8@*$A30)+CGEC=18!):*8`%9,D(=1/^@`-0&)1N
M#N1Y@V$L$F[VDA``8:8"".U#ZK9*A91@?$JT:T5.*P!?#L0]"]"+`Q[P';TD
MR%6V'$!I$?)9TB7!D4!4"`D!`+^S;/&V02F!$>ZID%8"UB"G4U!:M5L1`D11
M(C?(:['"-I$;5.>^!`&JB`8\HB)@3@"N<L]?BGO198*%,`)8*4*R2SBR36`@
M!XZH#:H32((D\+T&:6F"TH*NB#"J(C8@*&3?.9'U#8"_`Y'H0#30JB0(#@!&
M)(@-2G""$J#@<8MYBH-::!IV%16S04["6;:WP--.]5758^QS`2-;(C\$E!?A
M`:=NAP#G0L2]0H%('%V%/P'@\[;@\A3^6G*PL`!`,B$3>$E`BU"W`'@`-`%(
M,D5G*[<'@-@@L$U0CB.B@@TP^"%%`$''$I0`+SL$:X,9-$,PL$@;'T;2-T-,
M90&@@PW_Q<H$$5U1D[!!`23`!M4SHC%72-6!T+E^",%?8$;]D.G9UB(WP!Q1
M#R!AB"!4R@D9LVG;937,G6<[!PCH#Q+4ZU\R6R!`B&4#M+-23P>@PRR5ZT%<
M,*:[-5LA/7`!J#'B@F=N+W8R3LA9WN,02H>W!]4)K`50L!2P@,6#=B2,!,1;
MV?B!.8#ZL2=A,*"0.-)Z(#_8T0I)D"`$X'0A\1JW1I#@`@I\K`4E9H@6!^,!
MR09[``&`P&?^@$)>["$*VP-I(RX-TH($G3D)-H!L]`9RXP',W"!^C7=!D(#0
MO3UKD:U.0A5+<H.,,8@")G>(X!+4@!+T(.,$T0""($`DK](SW00IPGP[T,*Q
M'N@E$/S68LQ*D"&,CYE6&T)HBL78FB]0(`;O@&F`T(.@BV0(++!`U@@``1?8
MG2!D9:<`(K"!#X`@!"`X/(P&!$1!438]!>-Q"20O^18(JJ5!.8`&>.R!Z@W&
MMBT(RIT+LK"@)&`#/-X`08D:V(6-SF5$F&](CT`$&P"U[CP!`@J*MC426/0@
M,S`RE&QS7<!GCD$%0#Z#1I^$&L336)D#`("S/K[?ST!8T>$-A/_^O,TD$V0'
MV(<H!#)`,ZCSJP4;\`L%4"!QL:(@8KFIS56-2K;X$P:'P!3F82!0SH.0@``P
M5A`[L#:U$0`3D`,4(!L$EP0Y\#J'D4T%T3<#L``>0`-_QQ-&,$@8``$:H"U#
M1Q!&0`,DL('D48+>$1DBX'%'(`-\9(+?X1T%TT(Y(`(SL@`3\`$S\($$\5O"
M51`W$"![\2/EU`.%M``EH`(0X!W;91`T,`-8IRIEE`1/&!*U=P(P@@+XH8,"
M$2)D<01=^(5%,!8(X85@Z(4FHH,A\A#FAQ!I>$:TAR5FR!%]%51`\'8V400\
M0`,N(`,VH`-PF#"I@@0LXF,OYQ-$,`3^:G2!@,@32$`5.<`BBQB):Z&%DEB)
MEGB)F)B)FKB)G-B)GE@38D@1BOB);`$$&,!B-G`!.O`#%N`");`!1(($A2>%
M$#!`K$A*2?`!=P8U$@`!(#!#-%`O1KB&$X$#$-!$I,@1+D``*Q4:0&!,>P0`
MS#(#]F5:?)8$&%``!U`61```.W%*&W`S"T`$7_,V&V``MT81.F`^R?@1\[,O
M1_`<1_`X1%`"`H`PX$$D$C!S-```'"``0Y%`*$`$`C!ZE`4#-#``H(.%`G$$
M'O!..K`!3K&!&0`^0=`!$'`V25"'&3D4,S./))`!$A`M1S`"$%`!=.0X$T`!
M/=B.!H$Y"Q#^&;KS70Z0!"S`:0DY&CK`0I'T&\N&/2H0`$^AD`+1)2N@=0,@
M`7LU$$BP`+24`5PC`1^0`P\@`;&W`"Q0*SWP'2RP%\&Q`5_3=`TP59T')P``
M3`)@`ZQ!C"X920GP`"(@`D`QD`79?`!``Q!P8386-L\"`QL6/2U1!"@``(R#
M6=A#!"J`.1`05AE@`3H``-@C`S.#23@A-$6@`WYEF5T184<E-"*Y`P```4DR
M`'`2`!OP`J-(BB`T<SAA`P*I9&9B*$+G`(03;2LD+'?V`*ZB>@(1!`VP`#J@
M`6@C.#@D`@U``6JA`@Q``O8X,P!0%D(0!//3FT1P3CT``@E`%@G3``+]"`(H
M4`(DT!DR0&G3UY8&X1[(M`'2^"Q"`P0"4`"TU'P+@"H9D)9P`1X_```>T)0'
M``(>X!<S4`0"H`!`M1=9HF!"`P$04(]N)`,#P`(S(`#M,0`MP&TJ,#]$(`%J
M`6\'`P`FX`,9\`'.EP-```"X:)X&80(+BB@:0$LB(`%E<004$`$SI`$BY#O*
M0P(L^0!.*`$/$!D?,$,-=!@8T$(X4%("X0(*@$D2``0H]!<D$"*/<P`GP!(>
;4`0CV7S'F`32A&-.^@&.P0%3B*)DZA$!`0`[
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
